Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
AssigneeJanssen Biotech, Inc.
InventorsSheri Moores, Smruthi Vijayaraghavan
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
Claims80
A method of inducing trogocytosis from a donor cancer cell that expresses EGFR, c-Met, or EGFR and c-Met to an acceptor macrophage cell or an acceptor monocyte cell, the method comprising contacting the donor cancer cell with a bispecific anti-EGFR/c-Met antibody for a time sufficient to induce trogocytosis from the donor cancer cell to the acceptor macrophage cell or the acceptor monocyte cell,
- wherein the bispecific anti-EGFR/c-Met antibody comprises:
- a first domain that binds EGFR, wherein the first domain comprises a heavy chain complementarity determining region (HCDR1) comprising the amino acid sequence of SEQ ID NO:
- 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- and
- a second domain that binds c-Met, wherein the second domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 12.
A method of inducing trogocytosis from a donor cancer cell that expresses EGFR, c-Met, or EGFR and c-Met to an acceptor macrophage cell or an acceptor monocyte cell, the method comprising contacting the donor cancer cell with a bispecific anti-EGFR/c-Met antibody for a time sufficient to induce trogocytosis from the donor cancer cell to the acceptor macrophage cell or the acceptor monocyte cell,
- wherein the bispecific anti-EGFR/c-Met antibody comprises:
- a first domain that binds EGFR, wherein the first domain comprises a VH comprising the amino acid sequence of SEQ ID NO:
- 13 and a VL comprising the amino acid sequence of SEQ ID NO:
- 14;
- and a second domain that binds c-Met, wherein the second domain comprises a VH comprising the amino acid sequence of SEQ ID NO:
- 15 and a VL comprising the amino acid sequence of SEQ ID NO:
- 16.
A method of inducing trogocytosis from a donor cancer cell that expresses EGFR, c-Met, or EGFR and c-Met to an acceptor macrophage cell or an acceptor monocyte cell, the method comprising contacting the donor cancer cell with a bispecific anti-EGFR/c-Met antibody for a time sufficient to induce trogocytosis from the donor cancer cell to the acceptor macrophage cell or the acceptor monocyte cell,
- wherein the bispecific anti-EGFR/c-Met antibody comprises:
- a HC1 comprising the amino acid sequence of SEQ ID NO:
- 17, a LC1 comprising the amino acid sequence of SEQ ID NO:
- 18, a HC2 comprising the amino acid sequence of SEQ ID NO:
- 19, and a LC2 comprising the amino acid sequence of SEQ ID NO:
- 20.
Dependencies are inferred from the claim text.